OTCMKTS:NXEN Nexien BioPharma (NXEN) Stock Price, News & Analysis $0.0057 -0.01 (-47.71%) As of 01/21/2025 10:04 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsSEC FilingsShort Interest About Nexien BioPharma Stock (OTCMKTS:NXEN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nexien BioPharma alerts:Sign Up Key Stats Today's Range$0.0057▼$0.005750-Day Range$0.01▼$0.0252-Week Range$0.00▼$0.05Volume12,000 shsAverage Volume8,429 shsMarket Capitalization$403,389.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.Read More… Receive NXEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nexien BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address NXEN Stock News HeadlinesNXEN Nexien BioPharma, Inc.November 14, 2024 | seekingalpha.comNexien BioPharma, Inc. (NXEN)October 31, 2023 | finance.yahoo.comSee More Headlines NXEN Stock Analysis - Frequently Asked Questions How have NXEN shares performed this year? Nexien BioPharma's stock was trading at $0.0056 at the start of the year. Since then, NXEN shares have increased by 1.8% and is now trading at $0.0057. View the best growth stocks for 2025 here. How do I buy shares of Nexien BioPharma? Shares of NXEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nexien BioPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nexien BioPharma investors own include Labor Smart (LTNC), Acrivon Therapeutics (ACRV), Processa Pharmaceuticals (PCSA), Aurora Innovation (AUR), NVIDIA (NVDA), American Cannabis (AMMJ) and American Noble Gas (AMNI). Company Calendar Today1/22/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:NXEN CUSIPN/A CIK1625288 Webwww.nexienbiopharma.com Phone(303) 495-7583FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-240,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-3,028.21% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-0.57Miscellaneous Outstanding Shares70,770,000Free Float49,116,000Market Cap$403,389.00 OptionableNot Optionable Beta0.74 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report This page (OTCMKTS:NXEN) was last updated on 1/22/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredTrump currency shock imminentTrump's Quiet $1.9 Trillion Move Against the Fed A small army of Americans, with Trump's support, has launc...Stansberry Research | SponsoredJanuary 29th - the next big trading catalyst to watch Mark your calendar for January 29th. Because on that day, I believe we could see a $2 Trillion shock INTO t...Timothy Sykes | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nexien BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nexien BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.